Methotrexate shortage 'dire'

The US supply of the chemotherapy drug methtrexate is so severe that the current stores in hospitals may only be enough for two weeks, according to a report in the New York Times.

Calling the situation 'dire', Valerie Jensen, associate director of the Food and Drug Administration’s drug shortages program added that supplies "are just not meeting demand.”

This is an especially serious situation for children with acute lymphoblastic leukemia, an otherwise highly treatable disease that uses methotrexate to prevent the disease from spreading to the central nervous system.

The drug is also used in a variety of combination chemotherapy regimens, including those for breast cancer, some oral cancers, and some other hematologic cancers.

In the history of chemotherapy, methotrexate was the second drug ever developed after nitrogen mustard.

Source: New York Times

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap